$CRWV

CoreWeave's stock fell despite 110% Q4 revenue growth and $66.8B backlog, as $30-35B 2026 capex spending and debt concerns overshadow near-term guidance miss.

CoreWeave stock plunged 25% despite 110% revenue growth, as operating losses accelerate and the company plans massive $30-35B capex in 2026 amid heavy debt.

CoreWeave faces class action securities fraud lawsuit alleging overstatement of capacity and understatement of supplier risks between March-December 2025. Lead plaintiff applications due March 13, 2026.

Robbins LLP investigates CoreWeave ($CRWV) for allegedly misleading investors about demand capabilities and supplier risks. Stock fell from $183.58 to $69.50.

CoreWeave stock fell 18% post-earnings despite $5B revenue (160% growth) and $66B backlog, as investors fret over $30B capex plans and high leverage.

$CRWV faces class action suit alleging misleading statements about customer demand and vendor concentration risks. Investors who bought shares between March-December 2025 can join lawsuit.

CoreWeave investors have until March 13, 2026, to join securities fraud class action alleging misrepresented demand and concealed construction delays that triggered 16% stock decline.

Class action lawsuit filed against CoreWeave alleging false statements on demand capacity and undisclosed reliance on single data center supplier. Lead plaintiff deadline March 13.

Holzer & Holzer investigates Eos Energy after $969.6M loss disclosure. Firm examines whether investors received adequate financial disclosures.

CoreWeave stock dropped 20% despite 110% revenue growth to $1.57B, as massive losses and weak guidance disappointed investors concerned about profitability path.

CoreWeave shares fell 11% despite 110% revenue growth, as widening losses and weak forward guidance raised profitability concerns amid massive debt and negative cash flow.

Shareholder lawsuits filed against CoreWeave, Bath & Body Works, and Vistagen for alleged disclosure violations. Lead plaintiff deadlines set for March 2026.

CoreWeave faces securities class action for allegedly omitting material disclosures about operational risks and supply chain vulnerabilities. Investors with losses over $100K must apply by March 13, 2026.

CoreWeave's stock is volatile but backed by strong fundamentals: $56B revenue backlog, four-fold projected growth through 2027, and massive industry demand for AI infrastructure.

CoreWeave faces securities fraud lawsuit alleging false statements about operational capabilities and concealed business risks during 2025, following merger collapse and infrastructure delays.

CoreWeave's stock surged 140% with strong 133% sales growth, but the company faces profitability concerns, $19B debt, and dangerous customer concentration with two clients representing 77% of revenue.

Law firm Hagens Berman investigates CoreWeave for allegedly misleading investors about AI infrastructure capacity and concealing Denton facility delays, triggering $14 billion market cap decline.

Ark Investment increased positions in Figma, CoreWeave, and Recursion Pharmaceuticals Friday, buying growth stocks trading below 2025 peaks based on valuation opportunities and emerging tech trends.

Nvidia poised to beat earnings expectations with strong AI demand, while Intuit struggles with competitive AI threats to its core business, down 42.5% in three months.

CoreWeave faces securities fraud lawsuit for allegedly misrepresenting operational capabilities and failing to disclose supplier concentration risk, causing investor losses during March-December 2025.